Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Market Cap	405.81M
Revenue (ttm)	7.57M
Net Income (ttm)	-40.71M
Shares Out	5.53M
EPS (ttm)	-7.69
PE Ratio	n/a
Forward PE	169.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,810
Average Volume	18,354
Open	73.00
Previous Close	73.40
Day's Range	72.40 - 74.80
52-Week Range	31.20 - 77.00
Beta	0.69
RSI	82.31
Earnings Date	Nov 20, 2025

About WSE:CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 91
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CTX

Financial Performance

In 2024, WSE:CTX's revenue was 15.83 million, an increase of 19.88% compared to the previous year's 13.20 million. Losses were -38.43 million, -45.56% less than in 2023.